BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:58 PM
 | 
Sep 21, 2012
 |  BC Extra  |  Clinical News

Topotarget jumps on lymphoma data for belinostat

Topotarget A/S (CSE:TOPO) jumped DKK1.52 (135%) to DKK2.65 on Friday after reporting that once-daily IV belinostat met the primary endpoint of an objective response rate of 20% or greater in the pivotal Phase II BELIEF (PXD101-CLN-19) trial...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >